Intravenous immunoglobulin and febrile status epilepticus in children with Dravet syndrome: A retrospective multicentre study
Developmental Medicine & Child Neurology · 2025
DOI: 10.1111/dmcn.70077 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Developmental Medicine & Child Neurology, 2025. Verfasst von Romane Marc und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Neurology, Reference Centre for Rare Epilepsies, CHU Bordeaux, Bordeaux, France. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Status Epilepticus, Epilepsies, Myoclonic, Seizures, Febrile. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Aim
To assess the efficacy and tolerability of intravenous immunoglobulin (IVIG) in reducing febrile status epilepticus in children with Dravet syndrome.
Method
We conducted a retrospective multicentre study across seven French university hospitals (2005–2022). Children with genetically confirmed Dravet syndrome who received sequential IVIG were included. Clinical data were collected over two 6‐month periods: before and after IVIG initiation.
Results
Fourteen individuals (six males, eight females) were included. At IVIG initiation, all were in the stormy phase, aged 10 to 92 months, and receiving a median of four antiseizure medications. IVIG was administered every 1 to 6 weeks (0.3–0.5 g/kg per infusion). Hospitalizations for status epilepticus significantly decreased, from a median of 4 (range 0–16) at baseline to 1 (range 0–6) after treatment ( p = 0.002). Twelve individuals improved, two remained stable. Adverse events occurred in 6 out of 14 individuals, including infusion‐related fever or seizures. Central venous access was required in six cases. IVIG was continued beyond 6 months in 11 out of 14 individuals.
Interpretation
These series suggest a potential benefit of IVIG in reducing status epilepticus in selected children with Dravet syndrome. However, tolerability and feasibility issues were identified. A prospective controlled trial is warranted to further define the role of IVIG in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Paediatric Neurology, Reference Centre for Rare Epilepsies, CHU Bordeaux, Bordeaux, France.
- Department of Paediatric Neurology, Reference Centre for Rare Epilepsies, Enfants Malades University Hospital, AP-HP, Université Paris Cité, Paris, France.
- Université de Lorraine, CHRU-Nancy, Service de Pédiatrie, Reference Centre for Rare Epilepsies, Nancy, France.
- Université de Lorraine, IMoPA, Nancy, France.
- Department of Paediatric Neurology, Grenoble University Hospital, Grenoble, France.
- Department of Paediatric Neurology, Competence Centre for Rare Epilepsies, CHU Bicêtre, Le Kremlin Bicêtre, France.
ORCID-Profile: Romane Marc, Sylvie Nguyen The Tich, Claire Bar
Zitieren
APA
Marc, R., Chemaly, N., Kuchenbuch, M., Espil-Taris, C., Lametery, E., Maurey, H., Peudenier, S., Nguyen The Tich, S., Nabbout, R., & Bar, C. (2025). Intravenous immunoglobulin and febrile status epilepticus in children with Dravet syndrome: A retrospective multicentre study. Developmental Medicine & Child Neurology. https://doi.org/10.1111/dmcn.70077
Vancouver
Marc R, Chemaly N, Kuchenbuch M, Espil-Taris C, Lametery E, Maurey H, et al. Intravenous immunoglobulin and febrile status epilepticus in children with Dravet syndrome: A retrospective multicentre study. Developmental Medicine & Child Neurology. 2025. doi:10.1111/dmcn.70077
BibTeX
@article{Marc2025,
author = {Marc, Romane and Chemaly, Nicole and Kuchenbuch, Mathieu and Espil-Taris, Caroline and Lametery, Elodie and Maurey, Hélène and Peudenier, Sylviane and Nguyen The Tich, Sylvie and Nabbout, Rima and Bar, Claire},
title = {Intravenous immunoglobulin and febrile status epilepticus in children with Dravet syndrome: A retrospective multicentre study},
journal = {Developmental Medicine & Child Neurology},
year = {2025},
doi = {10.1111/dmcn.70077}
}
EUVIMED